Jefferies Rates Boston Scientific (BSX) buy, $67 Price Target

Jefferies Stays Bullish on Boston Scientific

Jefferies analyst Matthew Taylor kept a buy rating on Boston Scientific Corporation BSX on June 24, 2026, holding firm with a price target of $67. This update adds to the firm's ongoing coverage of major corporate names, following recent moves like its rating adjustments on Williams Companies and Marathon Petroleum earlier in the year. Taylor's target sits comfortably above where the shares currently change hands, reflecting an optimistic outlook compared to several peers on the street.

How Wall Street Views the Medical Device Maker

Other major financial firms have updated their outlooks on the Marlborough-based healthcare company through the autumn months. On October 14, 2026, Truist Securities maintained a buy rating while lowering its target from $57 to $51. Barclays initiated coverage on October 7, 2026, with an equal-weight rating and a $48 price target. Citigroup kept a neutral rating on October 5, 2026, with a target of $48, following an earlier downgrade from neutral on September 17, 2026, when its target went from $57 to $50. Wells Fargo kept an equal-weight rating on September 24, 2026, lowering its target to $48 from $50. Oppenheimer maintained an outperform rating on September 21, 2026, alongside a reduction in its target from $85 to $65. BTIG maintained a buy rating on September 9, 2026, with a $56 target, and TD Cowen reiterated a buy rating on August 25, 2026, with a $56 target. Overall, the stock carries a consensus buy recommendation from 29 analysts with a mean price target of $59.24, alongside a high target of $94 and a low target of $44.

Stock Price and Market Standing

Boston Scientific shares traded hands at $44.23 on Wednesday. The stock has experienced a wide trading band over the past year, reaching a 52-week low of $41.39 and a 52-week high of $105.65. The company currently has a market capitalization of roughly $64.0 billion and a price-to-earnings ratio of 17.9 based on trailing results, while its forward P/E sits at 13.1. Investors are looking ahead to the next scheduled earnings report on October 28, 2026, to gauge the medical device manufacturer's recent financial progress.

What Boston Scientific Does

Boston Scientific Corporation develops, manufactures, and markets medical devices used in interventional medical specialties around the globe. Its operations span the MedSurg and Cardiovascular segments, producing tools for gastrointestinal, urological, neurological, and heart rhythm disorders. These include everything from diagnostic scopes and laser systems to rhythm management devices and the WATCHMAN FLX left atrial appendage closure system. Founded in 1979, the company employs thousands of workers worldwide to support hospitals and clinics in treating complex patient conditions.

Looking Ahead After the Rating Update

Analyst updates like the one from Jefferies help shape market expectations as the company heads toward its late October earnings release. Investors will watch whether other financial institutions adjust their price targets to match shifting sector trends or if the consensus mean price of $59.24 holds steady. As always, individual analyst ratings reflect personal assessments by specific researchers and do not guarantee future stock price movements.